期刊文献+

丙戊酸钠协同阿霉素抑制MUTZ-1细胞株增效作用的研究

Inhibition of Adriamycin Combined with Sodium Valproate on MUTZ-1 Cell Line
原文传递
导出
摘要 目的:探讨丙戊酸钠协同阿霉素对MUTZ-1细胞株生长的抑制作用及其作用机制。方法:采用四甲基偶氮唑蓝(MTT)比色法观察药物对细胞生长的影响;发光比色法检测Caspase-3的活性。结果:小剂量丙戊酸钠可协同阿霉素抑制MUTZ-1细胞株生长,细胞生长抑制率在两药联合作用后比单独使用阿霉素明显增加,有剂量依赖性,与对照组相比有显著统计学意义。单药使用阿霉素时细胞的caspase-3活性上升,两药联合后caspase-3活性上升更明显。结论:小剂量的丙戊酸钠能增敏阿霉素诱导MUTZ-1细胞株发生凋亡,作用机制可能是通过上调caspase-3的活性来完成的。 Objective: To investigate the tumor suppression efficacy of histone deacetylase inhibitor,valproate sodium,in combination with Adriamycin in the treatment of myelodysplastic syndrome cell line MUTZ-1 and its mechanism. Methods: Logarithmic growth phase MUTZ-1 cell line was treated on different density of valproic acid,Adriamycin,alone or combination;after alone and combination. Caspase-3 activity was detected. Results: 0.25mmool/l valproate sodium did not show apoptosis effect, but can synergize Adriamycin to promote Apoptosis. it was concentration -dependent. All the data above were significantly different from that in control ( p〈 0.05). Aider treated with SVPA and ADM for 72h, the level ofcaspase-3 in MUTZ-1 was enhanced (P〈0.05). Conclusions: valproate sodium may enhance the efficacy of ADM in MUTZ-1 cell line. the mechanism of action is possibly through the activity ofcaspase-3.
作者 俞晨 陈宝安
出处 《现代生物医学进展》 CAS 2010年第16期3033-3036,共4页 Progress in Modern Biomedicine
基金 国家自然基金资助项目(30070318)
关键词 丙戊酸钠 骨髓增生异常综合症 MUTZ-1细胞株 细胞凋亡 Valproate Sodium MDS MUTZ-1 cell line Apoptosis
  • 相关文献

参考文献14

  • 1De Vane CL. Pharmaco kinetics, drug interactions, and tolerability of valproate[J]. Psychopharmacol Bull,2003,37(Suppl 2):25-42.
  • 2Steube KG, Gignac SM, Hu ZB,et al. In vitroculture studies of childhood myelodysplastic syndrome: establishment of the cell line MUTZ-1 [J]. Leuk Lymphoma, 1997; 25:345-363.
  • 3陈宝安,夏国华,李建勇,肖冰,邵泽叶,陈宁娜,高冲,吴雨洁.M-FISH用于骨髓增生异常综合征细胞株MUTZ-1复杂核型的检测分析(英文)[J].中国实验血液学杂志,2006,14(1):46-49. 被引量:10
  • 4戴体俊.合并用药的定量分析[J].中国药理学通报,1998,14(5):479-480. 被引量:136
  • 5Douglas C. Marchion, Elona Bicaku, et al.In vivo synergy between topoisomerase II and histone deacetylase inhibitors: predictive correlates[J].Mol Cancer Ther ,2005,4(12): 1993 -2000.
  • 6Karagiannis TC, Smith A J, ElOsta A. et al. Radio- and chemo-sensitization of human erythroleukemic K562 cells by the histone deacetylase inhibitor Trichostatin A. Molecular Radiation Biology[J], Hell J Nucl Med ,2004,;7(3): 184-91.
  • 7Kano Y, Akutsu M, Tsunoda S, et al. Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines. Division of Hematology[J].Tochigi Cancer Center, 2007, 25(1):31-40.
  • 8Louis M, Rosato RR, Battaglia E et al. Modulation of sensitivity to doxorubicin by the histone deacetylase inhibitor sodium butyrate in breast cancer cells[J]. Int J Oncol, 2005,26(6): 1569-74.
  • 9Daosukho C, Chert Y, Noel T, et al. Phenylbutyrate, a histone deacetylase inhibitor, protects against Adriamycin-induced cardiac injury[J]. Free Radic Biol Med, 2007, 15;42(12):1818-25.
  • 10Mster P, Marchion D, Bicaku E et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study[J]. J Clin Oncol,2007, 20;25(15): 1979-85.

二级参考文献9

  • 1Steube KG,Gignac SM,Hu ZB,et al.In vitro culture studies of childhood myelodysplastic syndrome:establishment of the cell line MUTZ-1.Leuk Lymphoma,1997 ; 25:345 - 363
  • 2Mitelman F.Guidelines for Cancer Cytogenetics,An international system for human cytogenetic nomenclature (ISCN).Basel:S karger,1995:1-114
  • 3Morrison LE,Legator MS.Evaluation of two-color ratio-coding in fluorescence in situ hybridization to chromosome targets.Cytometry,1997; 27:314-326
  • 4Tehinda J,Neumann TE,Volpert S,et al.Characterization of chromosomal rearrangements in hematological diseases using spectral karyotyping.Diagn Mol Pathol,2004; 13:190 - 195
  • 5Buchner T,Hiddemann W.Therapeutic strategies in acute myeloid leukemia.Internist (Berl).2002 ;43:1203 - 1204,1207 - 1211
  • 6Kraus J,Cohen M,Speicher MR.Multicolour FISH fine mapping unravels an insertion as a complex chromosomal rearrangement involving six breakpoints and a 5.89 Mb large deletion.J Med Genet,2003; 40:e60
  • 7Toyota M,Kopecky KJ,Toyota MO,et al.Methylation profiling in acute myeloid leukemia.Blood,2001;97:2823 -2829
  • 8戴体俊.协同、拮抗等定义亟待统一[J]生理科学进展,1997(04).
  • 9江明性.药理学[M]人民卫生出版社,1989.

共引文献142

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部